Other News

HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”)-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 (“FQ1 2026”) and provided a business update highlighting continued progress.

GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions

The anticipated acquisition aligns with GE HealthCare’s precision care strategy with the goal of strengthening the company’s portfolio of offerings in neurological care and its quantitative analysis of brain MRI icometrix’s icobrain platform – a comprehensive set of solutions for neurological disease analysis – includes icobrain aria, the first AI […]

JenaValve Announced ESC Guidelines Recognize TAVI as Class IIb Recommendation for Aortic Regurgitation

IRVINE, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the newly published guidelines from the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) include transcatheter aortic valve implantation (TAVI) as a treatment option for patients with severe, symptomatic aortic regurgitation (AR) when ineligible for surgery. This decision marks the first formal recommendation for TAVI in AR guidelines.

Catheter Precision Announces Tender Win and First Purchase Order in Croatia

FORT MILL, S.C., Sept. 10, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received the first purchase order from a hospital in Croatia after winning a competitive tender bid.

Realize Medical and Canon USA Partner to Redefine Procedural Planning Through Spatial Computing with VR and Imaging Technology

Collaboration aims to create the lab of the future, enabling safer, faster, and more precise interventions Key Benefits of Partnership  Integration of VR and imaging: Combines Realize Medical’s VR platform with Canon’s imaging solutions for an immersive and streamlined procedural planning experience. Enhanced clinical decision-making support: Enables safer, faster, and more precise interventions through advanced visualization. Future-ready technology: Builds the foundation for the connected, intelligent interventional lab of the future. Clinical focus areas: Initial applications in pediatric cardiology and adult structural heart disease, with broader expansion planned.  OTTAWA, Ontario, Sept. 10, 2025 (GLOBE NEWSWIRE) — Realize Medical and Canon USA, Inc. today announced a strategic partnership to combine Realize Medical’s cutting-edge VR platform with Canon’s advanced imaging solutions, setting a new standard for procedural planning in interventional medicine. This collaboration combines the power of spatial computing with world-class medical imaging to accelerate safer, faster, and more precise interventions — a critical step toward creating the lab of the future.  “Canon shares our vision for a more connected, intelligent procedural suite,” said Justin Sutherland, Ph.D., Chief Executive Officer of Realize Medical. “This partnership not only enables broader access to Elucis but also accelerates our joint mission to transform clinical decision-making through spatial computing.”  The initial focus of this collaboration will be in pediatric cardiology and adult structural heart disease, with plans to expand into additional interventional specialties in the future.  “The lab of the future will give physicians the ability to plan interventions in a fully immersive mixed reality environment – improving clarity, confidence, and care,” said Jaimin Chung, Managing Director, IXR/VL BU, Canon USA. “Guided by our Made for Life philosophy, Canon Medical’s collaboration with Realize Medical brings this innovation to pediatric intervention today with new applications for adult care already on the horizon.” Realize Medical and Canon USA will showcase their integrated technologies at the Transcatheter Cardiovascular Therapeutics Annual Meeting from October 25–28, 2025, in San Francisco, CA. Representatives are invited to visit Realize Medical in the Canon Medical Booth #1657 for hands-on demonstrations with Elucis.   Media Contact at Realize Medical  Melissa Kois Marketing Lead melissa@realizemed.com | 647-962-9057 www.realizemed.com   Media Contact at Canon USA  Oliva DuarteDirector, Corporate Communicationsoduarte@us.medical.canon | 831-877-0590https://us.medical.canon/

BioSig Technologies, Inc. Announces Corporate Rebrand to Streamex Corp.

Strategic Rebranding to Focus on Expanded Business Model and Growth Strategy. New Ticker Symbol “STEX”.LOS ANGELES & VANCOUVER, British Columbia, Sept. 10, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig”), which recently merged with Streamex Exchange Corporation (“Streamex”) (together, “BSGM” or the “Company”), announced today that it will change its name to Streamex Corp., effective at 12:01 am Eastern Time on Friday, September 12, 2025. In connection with the name change, the Company will change its trading symbol to “STEX.” The Company’s common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on September 12, 2025. As of September 12, 2025, all Company stock trading, filings, and market related information will be reported under the new symbol “STEX”. The Company’s CUSIP number will remain unchanged, and no action is required from shareholders. No other aspects of the Company’s corporate structure or operations are impacted by the ticker symbol change. About Streamex Exchange Corporation Streamex is a Real World Asset (“RWA”) tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. About BioSig Technologies, Inc. BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition will be obtained, and whether we will be able to maintain compliance with Nasdaq’s listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20250714401245/en/ Investor Relations ContactAdele CareyAlliance Advisors Investor Relationsacarey@allianceadvisors.com  Henry McPhieCEO of BioSig, Co-Founder of Streamexcontact@Streamex.comhttps://www.streamex.com/https://x.com/streamexSource: BioSig and Streamex